Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1677277 | 0.88 | MEN1 (0.54) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 | |
| SCHEMBL14341838 | 0.81 | KMT2A (0.63) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 | |
| SCHEMBL13652574 | 0.81 | KMT2A (0.68) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 | |
| SCHEMBL2280187 | 0.81 | ALDH1A1 (0.69) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 | |
| SCHEMBL12422573 | 0.81 | EPHX2 (0.59) | MEN1KMT2AEPHX2 | |
| SCHEMBL660424 | 0.80 | ALDH1A1 (0.68) | EPHX2ALDH1A1L3MBTL1MAPTP2RX7 | |
| SCHEMBL16039630 | 0.78 | KDM4E (0.57) | MEN1KMT2AEPHX2ALDH1A1 | |
| SCHEMBL14503280 | 0.78 | MEN1 (0.67) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16678441 | 0.76 | GRIN1 (0.51) | MEN1KMT2AEPHX2ALDH1A1 | |
| SCHEMBL3583903 | 0.76 | KMT2A (0.65) | MEN1KMT2AEPHX2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| WO-1999018065-A1 | CHIRAL AMINES | CHIROTECH TECHNOLOGY LIMITED (GB) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | MEN1 4127/4885KMT2A 3209/4885EPHX2 1146/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | MEN1 4127/4885KMT2A 3209/4885EPHX2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.